Picture [iito] No Tracking 650x80px
Document › Details

ReproCell, Inc.. (11/24/15). "Press Release: Regarding the Synergy Effect of Making Biopta Limited a Wholly-owned Subsidiary".

Organisations Organisation Biopta Ltd.
  Today Reprocell Europe Ltd.
  Group ReproCell (Group)
  Organisation 2 ReproCell Inc. (JP)
  Group ReproCell (Group)
Products Product drug discovery services
  Product 2 iPSC technology (induced pluripotent stem cell technology)
Index terms Index term Biopta–ReproCell: investment, 201511–201512 acquisition 100% of Biopta Ltd + its sub Biopta Inc by ReproCell
  Index term 2 Stemgent–ReproCell: investment, 201410 acquisition of iPS cell business of Stemgent by ReproCell USA renamed Stemgent
Persons Person Yokoyama, Chikafumi (ReproCell 201511 CEO)
  Person 2 Bunton, David (Biopta 201511 CEO + Co-Founder)

Company: ReproCELL, Inc. (JASDAQ Company code: 4978)
Representative: Chikafumi Yokoyama, PhD

At a meeting of the board of directors of this company on November 24th, 2015, a decision has been made regarding the acquisition of 100% of the ordinary shares of the UK firm, Biopta Limited (“Biopta”) and its integration as a wholly-owned subsidiary. Information regarding the purpose and summary of this acquisition, as well as the ensuing synergy effect, is detailed below.

1. The purpose and summary of the acquisition of Biopta

The acquisition ofBiopta is aimed at strengthening the pharmaceutical industry-targeteddrug discovery support aspect of our business, which is one of the mainstays of our company. Biopta provides drug discovery support services to pharmaceutical companies —their main customersincluding Big Pharma in Europe, North America and Japan. These services primarily consistof research using human living tissuesinpreclinical studies that are more predictive of the human response to drugs than the animal experiments upon which the pharmaceutical companies have traditionallyrelied. Outsourcing of such early stage drug discoveryservicesis increasingly rapidly. Presently, due to their high costs and their need to be conducted over long time periods, there is a rapidly growing trend away fromanimal experiments that pharmaceutical manufacturers conduct in-house towardsoutsourced pharmaceutical support services that can be conducted atlowercostand in shorter periods of time. The global spend on drug discovery-related research and development by pharmaceutical manufacturers totals over 7 trillion yen per annum, and exploratory research and preclinical studies are said to account for around 1.75 trillion yen (25% of the total) of that sum. A further market driver is the development of ‘precisionmedicines’, which necessarily rely on human cells and tissues in early drug discovery. The rapidly expanding drug discovery support service industrythereforeholds great potential in this market.

In this field,Biopta is a pioneering developer of drug discovery support services, taking an integrated approach to the provision of human tissuesand preclinical contract research(CRO services)using ethically-sourced human tissues.The company is strongly competitive and has many achievements, backed by their high levels of technological prowess. By adding Biopta’s drug discovery support services to our existing services (human cell products), our group aims to expand our operations in the corresponding market sector, as well as constructing a strong business portfolio aimed at entering the field of regenerative medicine through the synergy of the two companies’ competitiveness.

An overview of Biopta:

Company: Biopta Limited

Address: Weipers Centre, Garscube Estate, Bearsden Road, Glasgow, G61 1QH, UK

Name and Position of Representative: CEO David Cameron Bunton

Business Outline:
Drug discovery support services (CRO services)
CRO Services: Research and preclinical laboratoryservices for pharmaceutical businesses using ethically-sourced human tissues.

Capital Stock: 2,129,000 GBP

Founding Date: 2002

Subsidiaries: Biopta Inc. (USA)

Number of Employees: 18 (Group)

Record changed: 2019-06-09


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for ReproCell (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top